Skip to main content
NCBI home page
Molecular Pathology : MP logoLink to Molecular Pathology : MP
. 1999 Apr;52(2):78–83. doi: 10.1136/mp.52.2.78

Concerted overexpression of the genes encoding p21 and cyclin D1 is associated with growth inhibition and differentiation in various carcinomas.

J S de Jong 1, P J van Diest 1, R J Michalides 1, J P Baak 1
PMCID: PMC395678  PMID: 10474686

Abstract

AIMS: To investigate the expression of the genes encoding cyclin D1 and p21 in proliferative and non-proliferative cells, as demonstrated by the Ki67 antibody, and to correlate these findings with differentiation. METHODS: Immunohistochemistry and immunofluorescence double staining were performed on three breast cancers, two squamous cell cancers of the head and neck, and one ovarium cystadenocarcinoma. In addition, the in vitro effect of cyclin D1 on p21 gene expression in MCF7 breast cancer cells was evaluated. RESULTS: Immunofluorescence double staining showed a differentiation related gradient in the detection of the Ki67 antigen, cyclin D1, and p21 in squamous cell cancers of the head and neck: Ki67 was detected in the basal layers of the tumour and the cyclin D1 and p21 genes were coexpressed in the higher, more differentiated layers of the tumour. The breast and ovarian cancers often had cells that coexpressed the p21 and cyclin D1 genes, whereas coexpression of cyclin D1 and Ki67 did not occur. Western blot analysis of the MCF7 breast cancer cells showed an upregulation of p21 production when cyclin D1 gene expression was induced. CONCLUSION: Overexpression of the cyclin D1 gene seems to lead to growth arrest in a variety of human cancers, possibly through the induction of p21 by cyclin D1. In squamous cell cancer, concerted overexpression of the genes encoding cyclin D1 and p21 might also induce differentiation.

Full Text

The Full Text of this article is available as a PDF (213.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbareschi M., Pelosio P., Caffo O., Buttitta F., Pellegrini S., Barbazza R., Dalla Palma P., Bevilacqua G., Marchetti A. Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. Int J Cancer. 1997 Apr 22;74(2):171–174. doi: 10.1002/(sici)1097-0215(19970422)74:2<171::aid-ijc5>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  2. Bartkova J., Lukas J., Müller H., Strauss M., Gusterson B., Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res. 1995 Feb 15;55(4):949–956. [PubMed] [Google Scholar]
  3. Bobrow M. N., Litt G. J., Shaughnessy K. J., Mayer P. C., Conlon J. The use of catalyzed reporter deposition as a means of signal amplification in a variety of formats. J Immunol Methods. 1992 Jun 24;150(1-2):145–149. doi: 10.1016/0022-1759(92)90073-3. [DOI] [PubMed] [Google Scholar]
  4. Chen X., Bargonetti J., Prives C. p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res. 1995 Oct 1;55(19):4257–4263. [PubMed] [Google Scholar]
  5. Doglioni C., Pelosio P., Laurino L., Macri E., Meggiolaro E., Favretti F., Barbareschi M. p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol. 1996 Jul;179(3):248–253. doi: 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  6. Erber R., Klein W., Andl T., Enders C., Born A. I., Conradt C., Bartek J., Bosch F. X. Aberrant p21(CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer. 1997 Aug 22;74(4):383–389. doi: 10.1002/(sici)1097-0215(19970822)74:4<383::aid-ijc4>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  7. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547–5551. doi: 10.1073/pnas.89.12.5547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Graña X., Reddy E. P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995 Jul 20;11(2):211–219. [PubMed] [Google Scholar]
  9. Guillot C., Falette N., Paperin M. P., Courtois S., Gentil-Perret A., Treilleux I., Ozturk M., Puisieux A. p21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours. Oncogene. 1997 Jan 9;14(1):45–52. doi: 10.1038/sj.onc.1200803. [DOI] [PubMed] [Google Scholar]
  10. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67–108. doi: 10.1016/s0065-230x(08)60352-8. [DOI] [PubMed] [Google Scholar]
  11. Han E. K., Sgambato A., Jiang W., Zhang Y. J., Santella R. M., Doki Y., Cacace A. M., Schieren I., Weinstein I. B. Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene. 1995 Mar 2;10(5):953–961. [PubMed] [Google Scholar]
  12. Hiyama H., Iavarone A., LaBaer J., Reeves S. A. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene. 1997 May 29;14(21):2533–2542. doi: 10.1038/sj.onc.1201080. [DOI] [PubMed] [Google Scholar]
  13. Koff A., Giordano A., Desai D., Yamashita K., Harper J. W., Elledge S., Nishimoto T., Morgan D. O., Franza B. R., Roberts J. M. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science. 1992 Sep 18;257(5077):1689–1694. doi: 10.1126/science.1388288. [DOI] [PubMed] [Google Scholar]
  14. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  15. Lammie G. A., Peters G. Chromosome 11q13 abnormalities in human cancer. Cancer Cells. 1991 Nov;3(11):413–420. [PubMed] [Google Scholar]
  16. Landberg G., Nielsen N. H., Nilsson P., Emdin S. O., Cajander J., Roos G. Telomerase activity is associated with cell cycle deregulation in human breast cancer. Cancer Res. 1997 Feb 1;57(3):549–554. [PubMed] [Google Scholar]
  17. Lew D. J., Dulić V., Reed S. I. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell. 1991 Sep 20;66(6):1197–1206. doi: 10.1016/0092-8674(91)90042-w. [DOI] [PubMed] [Google Scholar]
  18. Liu Y., Martindale J. L., Gorospe M., Holbrook N. J. Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res. 1996 Jan 1;56(1):31–35. [PubMed] [Google Scholar]
  19. Lukas J., Bartkova J., Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol. 1996 Dec;16(12):6917–6925. doi: 10.1128/mcb.16.12.6917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Marchetti A., Doglioni C., Barbareschi M., Buttitta F., Pellegrini S., Bertacca G., Chella A., Merlo G., Angeletti C. A., Dalla Palma P. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene. 1996 Mar 21;12(6):1319–1324. [PubMed] [Google Scholar]
  21. Matsuoka S., Edwards M. C., Bai C., Parker S., Zhang P., Baldini A., Harper J. W., Elledge S. J. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995 Mar 15;9(6):650–662. doi: 10.1101/gad.9.6.650. [DOI] [PubMed] [Google Scholar]
  22. Michalides R. J., van Veelen N. M., Kristel P. M., Hart A. A., Loftus B. M., Hilgers F. J., Balm A. J. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1997 May;123(5):497–502. doi: 10.1001/archotol.1997.01900050045005. [DOI] [PubMed] [Google Scholar]
  23. Michalides R., Hageman P., van Tinteren H., Houben L., Wientjens E., Klompmaker R., Peterse J. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer. 1996 Mar;73(6):728–734. doi: 10.1038/bjc.1996.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Michalides R., van Veelen N., Hart A., Loftus B., Wientjens E., Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 1995 Mar 1;55(5):975–978. [PubMed] [Google Scholar]
  25. Motokura T., Arnold A. Cyclins and oncogenesis. Biochim Biophys Acta. 1993 May 25;1155(1):63–78. doi: 10.1016/0304-419x(93)90022-5. [DOI] [PubMed] [Google Scholar]
  26. Motokura T., Bloom T., Kim H. G., Jüppner H., Ruderman J. V., Kronenberg H. M., Arnold A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991 Apr 11;350(6318):512–515. doi: 10.1038/350512a0. [DOI] [PubMed] [Google Scholar]
  27. Musgrove E. A., Lee C. S., Buckley M. F., Sutherland R. L. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8022–8026. doi: 10.1073/pnas.91.17.8022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Nurse P. Universal control mechanism regulating onset of M-phase. Nature. 1990 Apr 5;344(6266):503–508. doi: 10.1038/344503a0. [DOI] [PubMed] [Google Scholar]
  29. Pagano M., Theodoras A. M., Tam S. W., Draetta G. F. Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev. 1994 Jul 15;8(14):1627–1639. doi: 10.1101/gad.8.14.1627. [DOI] [PubMed] [Google Scholar]
  30. Poluha W., Poluha D. K., Chang B., Crosbie N. E., Schonhoff C. M., Kilpatrick D. L., Ross A. H. The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol Cell Biol. 1996 Apr;16(4):1335–1341. doi: 10.1128/mcb.16.4.1335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Quelle D. E., Ashmun R. A., Shurtleff S. A., Kato J. Y., Bar-Sagi D., Roussel M. F., Sherr C. J. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 1993 Aug;7(8):1559–1571. doi: 10.1101/gad.7.8.1559. [DOI] [PubMed] [Google Scholar]
  32. Resnitzky D., Reed S. I. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol. 1995 Jul;15(7):3463–3469. doi: 10.1128/mcb.15.7.3463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Robles A. I., Larcher F., Whalin R. B., Murillas R., Richie E., Gimenez-Conti I. B., Jorcano J. L., Conti C. J. Expression of cyclin D1 in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7634–7638. doi: 10.1073/pnas.93.15.7634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Rosenberg A. R., Zindy F., Le Deist F., Mouly H., Métézeau P., Bréchot C., Lamas E. Overexpression of human cyclin A advances entry into S phase. Oncogene. 1995 Apr 20;10(8):1501–1509. [PubMed] [Google Scholar]
  35. Rosenberg C. L., Wong E., Petty E. M., Bale A. E., Tsujimoto Y., Harris N. L., Arnold A. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9638–9642. doi: 10.1073/pnas.88.21.9638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993 Dec 16;366(6456):704–707. doi: 10.1038/366704a0. [DOI] [PubMed] [Google Scholar]
  37. Sherr C. J. Mammalian G1 cyclins. Cell. 1993 Jun 18;73(6):1059–1065. doi: 10.1016/0092-8674(93)90636-5. [DOI] [PubMed] [Google Scholar]
  38. Sutherland R. L., Hamilton J. A., Sweeney K. J., Watts C. K., Musgrove E. A. Expression and regulation of cyclin genes in breast cancer. Acta Oncol. 1995;34(5):651–656. doi: 10.3109/02841869509094043. [DOI] [PubMed] [Google Scholar]
  39. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994 Jul 15;78(1):67–74. doi: 10.1016/0092-8674(94)90573-8. [DOI] [PubMed] [Google Scholar]
  40. Tron V. A., Tang L., Yong W. P., Trotter M. J. Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma. Am J Pathol. 1996 Oct;149(4):1139–1146. [PMC free article] [PubMed] [Google Scholar]
  41. Uhlman D. L., Adams G., Knapp D., Aeppli D. M., Niehans G. Immunohistochemical staining for markers of future neoplastic progression in the larynx. Cancer Res. 1996 May 1;56(9):2199–2205. [PubMed] [Google Scholar]
  42. Wang T. C., Cardiff R. D., Zukerberg L., Lees E., Arnold A., Schmidt E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994 Jun 23;369(6482):669–671. doi: 10.1038/369669a0. [DOI] [PubMed] [Google Scholar]
  43. Winston J. T., Pledger W. J. Growth factor regulation of cyclin D1 mRNA expression through protein synthesis-dependent and -independent mechanisms. Mol Biol Cell. 1993 Nov;4(11):1133–1144. doi: 10.1091/mbc.4.11.1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Withers D. A., Harvey R. C., Faust J. B., Melnyk O., Carey K., Meeker T. C. Characterization of a candidate bcl-1 gene. Mol Cell Biol. 1991 Oct;11(10):4846–4853. doi: 10.1128/mcb.11.10.4846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993 Dec 16;366(6456):701–704. doi: 10.1038/366701a0. [DOI] [PubMed] [Google Scholar]
  46. Yang Z. Y., Perkins N. D., Ohno T., Nabel E. G., Nabel G. J. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med. 1995 Oct;1(10):1052–1056. doi: 10.1038/nm1095-1052. [DOI] [PubMed] [Google Scholar]
  47. Zeng Y. X., el-Deiry W. S. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene. 1996 Apr 4;12(7):1557–1564. [PubMed] [Google Scholar]
  48. Zhang H., Hannon G. J., Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 1994 Aug 1;8(15):1750–1758. doi: 10.1101/gad.8.15.1750. [DOI] [PubMed] [Google Scholar]
  49. Zwijsen R. M., Klompmaker R., Wientjens E. B., Kristel P. M., van der Burg B., Michalides R. J. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol Cell Biol. 1996 Jun;16(6):2554–2560. doi: 10.1128/mcb.16.6.2554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. de Boer C. J., van Krieken J. H., Kluin-Nelemans H. C., Kluin P. M., Schuuring E. Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene. 1995 May 4;10(9):1833–1840. [PubMed] [Google Scholar]
  51. el-Deiry W. S., Harper J. W., O'Connor P. M., Velculescu V. E., Canman C. E., Jackman J., Pietenpol J. A., Burrell M., Hill D. E., Wang Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994 Mar 1;54(5):1169–1174. [PubMed] [Google Scholar]
  52. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. doi: 10.1016/0092-8674(93)90500-p. [DOI] [PubMed] [Google Scholar]
  53. van Diest P. J., Michalides R. J., Jannink L., van der Valk P., Peterse H. L., de Jong J. S., Meijer C. J., Baak J. P. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol. 1997 Feb;150(2):705–711. [PMC free article] [PubMed] [Google Scholar]

Articles from Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES